Close Menu

NEW YORK (GenomeWeb) – Roche said today that its diagnostics revenues grew 5 percent year over year for the first quarter of 2018, driven by growth across the entire Dx division.

For the three months ended March 31, the Swiss pharmaceutical and diagnostics company reported overall revenues of CHF 13.58 billion ($13.85 billion), up 5 percent from CHF 12.94 billion in Q1 2017.

In diagnostics, Roche reported revenues of CHF 2.91 billion, up from CHF 2.77 billion in 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.